SQLite Web: event_store.db

Update row 129331 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-18T03:05:05.644967+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:3ab2da7fe13cb944","evidence_event_ids":["evt_a22fcfba7d5e"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-161582.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-161582.txt","company":"Trevi Therapeutics, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-161582.txt","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_66d58273065cb61e","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-161582.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:27:20.074032+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"424B5","final_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-161582.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-161582.txt","source_event_id":"evt_a22fcfba7d5e","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"424B5","fp":"ca7ec0a198d7ea7b","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-16","2026-04-17","2026-04-18","2026-04-20","2025-11-13"],"entities":[{"asset_class":"equity","name":"Trevi Therapeutics, Inc.","relevance":"high","symbol":"TRVI","type":"issuer"},{"asset_class":"equity_market","name":"Nasdaq Global Market","relevance":"medium","symbol":"","type":"exchange"},{"asset_class":"regulator","name":"Securities and Exchange Commission (SEC)","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; no prior filing text/state is included for comparison.","The filing\u2019s specific purpose beyond the offering (e.g., amendment to prior prospectus terms) is not explicitly described beyond general prospectus-supplement update language.","The public offering price per share is not stated directly in the provided text (only referenced as \u201cpublic offering price per share\u201d).","No details are provided here on use of proceeds, underwriting syndicate members, or risk factor specifics beyond generic references."],"key_facts":["Form type: 424B5 (prospectus supplement) filed pursuant to Rule 424(b)(5) (Registration No. 333-291517).","Issuer: Trevi Therapeutics, Inc.; common stock listed on Nasdaq Global Market under symbol \u201cTRVI.\u201d","Offering size: 11,600,000 shares of common stock offered in this offering.","Last reported sale price on April 16, 2026: $14.54 per share.","Company status: Trevi is a \u201csmaller reporting company\u201d and elected to comply with reduced public company disclosure requirements for this prospectus supplement and future filings.","Underwriters\u2019 option: 30 days to purchase up to an additional 1,740,000 shares at the public offering price per share, less underwriting discounts and commissions.","If option exercised in full: total underwriting discounts and commissions payable by us = $10,405,200; total proceeds to us before expenses = $163,014,800.","Expected delivery of shares to investors: on or about April 20, 2026.","Prospectus supplement dated April 16, 2026; document states it updates/adds to information in an accompanying prospectus dated November 13, 2025."],"numeric_claims":[{"label":"Shares offered","value":"11,600,000"},{"label":"Underwriters option shares (max)","value":"1,740,000"},{"label":"Last reported sale price (Apr 16, 2026)","value":"$14.54 per share"},{"label":"Underwriters option period","value":"30 days"},{"label":"Underwriting discounts/commissions if option full","value":"$10,405,200"},{"label":"Total proceeds to us before expenses if option full","value":"$163,014,800"},{"label":"Expected delivery date","value":"on or about April 20, 2026"}],"primary_claim":"TRVI (Trevi Therapeutics, Inc.) filed a Form 424B5 prospectus supplement for an offering of 11,600,000 shares of common stock, with an underwriters\u2019 30-day option for up to 1,740,000 additional shares.","relevance_score":0.72,"sentiment":"neutral","source_quality":"high","summary":"Trevi Therapeutics, Inc. filed a Form 424B5 prospectus supplement for an offering of 11,600,000 shares of its common stock. The filing also discloses an underwriters\u2019 option to purchase up to an additional 1,740,000 shares and provides pricing/terms and expected delivery timing.","topics":["SEC filing","prospectus supplement","common stock offering","underwriters option","Nasdaq listing","smaller reporting company"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 424B5 \u00b7 Trevi Therapeutics, Inc. \u00b7 Filed 20260417","ticker":"TRVI","tickers":["TRVI"],"title":"TRVI filed 424B5","url":"https://www.sec.gov/Archives/edgar/data/1563880/0001193125-26-161582.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel